BioStock: SynAct Pharma’s CEO comments on EXPAND data

SynAct Pharma has announced disappointing top-line data from its 12-week EXPAND phase IIb clinical trial. The study is evaluating the drug candidate resomelagon in newly diagnosed rheumatoid arthritis patients with severe disease. Results show a high placebo effect thus not achieving the primary endpoint – a statistically higher rate of 20 improvement in the American College of Rheumatology score compared to placebo. BioStock spoke to CEO Torbjørn Bjerke about the results.  

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/synact-pharmas-ceo-comments-on-expand-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se